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ABSTRACT: Background. Squamous cell carcinoma (SCC) and basal
cell carcinoma (BCC) are the 2 most common cutaneous carcinomas.
Molecular profiles predicting metastasis of these cancers have not been
identified.
Methods. Epigenetic profiles of 37 primary cases of cutaneous SCC and
BCC were quantified via the Illumina Goldengate Cancer Panel. Differen-
tial protein expression by metastatic potential was analyzed in 110 total
cases by immunohistochemical (IHC) staining.
Results. Unsupervised hierarchical clustering analysis revealed that met-
astatic BCCs had a methylation profile resembling cutaneous SCCs. Met-
astatic cutaneous SCCs were found to be hypermethylated at FRZB
(median methylation: 46.7% vs 4.7%; p 5 4 3 1025). Metastatic BCCs
were found to be hypomethylated at MYCL2 (median methylation: 3.8%
vs 83.4%; p 5 1.9 3 1026). Immunohistochemical staining revealed
few differences between metastatic and nonmetastatic cancers.
Conclusion. Metastatic primary BCCs and cutaneous SCCs had distinct
epigenetic profiles when compared to their nonmetastatic counterparts.
Epigenetic profiling may prove useful in future diagnosis and prevention
of advanced nonmelanoma skin cancers. VC 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC) are the 2 most common cutaneous
malignancies in the United States. Most nonmelanoma
skin cancers remain localized and noninvasive; however,
there is a risk of locoregional and distant spread of dis-
ease with both cutaneous SCC and BCC. Cutaneous SCC
has a risk of metastasis, which has been reported between
2% and 9.9%.1–7 Despite the high incidence of BCC, met-
astatic transformation is extremely rare with an estimated
rate of metastasis between 0.0028% and 0.55%.8–11 In
recent decades, much has been learned about the meta-
static potential of cutaneous SCC. Risk factors, such as
primary location, tumor size, depth of invasion, immuno-
suppression, and perineural invasion have all been associ-
ated with increased risk of metastasis.12–16 Risk factors
associated with the metastasis of BCC have been reported
despite the rarity of its occurrence. Metastatic BCC tends
to arise preferentially from tumors in the head and neck
region, which account for 70% to 80% of reported cases
in the literature, with ear, cheek, and forehead predomi-
nating.8,10,11 The size of the primary tumor seems to be
an important risk factor with large, neglected tumors
comprising many of the reported cases in the literature.
Snow et al,10 in their series of metastatic BCC, found that
75% of metastatic tumors occurred in tumors >2 cm and/
or with invasion of bone or other deep structures.
Epigenetic modifications, including DNA methylation,
have been shown to play an integral role in carcinogenesis,
cancer progression, and metastasis. Compared to normal
tissues, tumors tend to be hypomethylated at intergenic dis-
tal regulatory regions and repetitive elements, which gener-
ally results in genomic instability, and hypermethylated at
gene promoters, resulting in gene silencing.17 Additionally,
epigenetic modifications are known to regulate gene
expression patterns and affect cell fate decisions.18 Thus,
quantification of epigenetic profiles across the genome can
establish similarities or differences in tumor cell type of
origin and can provide insight as to whether rare metastatic
basal cancers actually represent a basal-like differentiation
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of SCCs. Epigenetic biomarkers of metastatic potential
have previously been identified in malignant melanoma,19
however, it is unknown if primary cutaneous SCCs and
BCCs with metastatic potential have a distinct epigenetic
profile. The high incidences of these cancers make the
identification of novel biomarkers of metastasis in these
tumors of high clinical utility.
Despite numerous reports citing risk factors associated
with metastatic skin cancers, many patients with high-risk
features, such as large size and invasion of bone, do not
develop regional or distant metastases. A central question
is how to more precisely identify the patients with cutane-
ous SCC or BCC that have a high potential to metasta-
size. To address this question, we undertook a study of
the epigenetic profiles of a cohort of patients from the
University of Michigan Cancer Center with documented
metastasis of cutaneous SCC or BCC and compared their
epigenetic signatures to an age-matched control group of
nonmetastatic cutaneous SCC or BCC specimens, respec-
tively, to determine unique patterns that might be associ-
ated with metastatic disease in each malignancy.
MATERIALS AND METHODS
Identification of cases
Institutional Review Board approval at the University
of Michigan was prospectively obtained (HUM00028920)
and cases of metastatic cutaneous SCC and BCC were
identified in a systematic chart review of all surgical
cases performed in the Department of Otolaryngology–
Head and Neck Surgery at the University of Michigan
between 1990 and 2010. Medical records for these
patients were examined and pertinent data were collected
regarding patient demographics, tumor pathology, and
course of disease. Surgical specimens were collected to
confirm histopathologic characteristics and presence of
cutaneous SCC or BCC in primary and metastatic tumor
by an experienced head and neck pathologist (J.B.M.).
Medical records and specimens were scrutinized accord-
ing to the criteria set forth by Lattes and Kessler20 in
1951, and adapted by the Cotran21 review in 1961, which
states that an accurate diagnosis of metastatic BCC must
satisfy the following criteria: (1) the primary lesion must
be of cutaneous origin; (2) metastases must be distin-
guished from growth by direct extension of the original
tumor; and (3) the primary and metastatic tissue must
share similar histologic subtypes. These criteria were sim-
ilarly applied for patients with metastatic cutaneous SCC.
Formalin-fixed paraffin-embedded tissue, DNA isolation,
and bisulfite conversion
Paraffin blocks containing pathologic tissue from both
primary and metastatic cutaneous SCC and BCC tumors
were obtained from the University of Michigan Pathology
Core. In order to provide an experimental control group
for patients with metastatic cutaneous SCC or BCC, par-
affin blocks from age-matched patients that did not meta-
stasize were randomly selected in a 1:2 ratio. Tumor
blocks were recut for uniform histopathologic review and
microdissection, with the first and last slides of a series
of 12 reviewed by a qualified pathologist (J.M.) to con-
firm the original diagnosis and to circle areas for DNA
extraction. Percent cellularity was estimated for each
tumor, and areas with >70% cancer cellularity were des-
ignated for use in the analyses.
Tumor regions that were identified for DNA extraction
were cored from the formalin fixed paraffin embedded
tissue blocks using an 18 gauge needle. DNA was iso-
lated from the cored tissue samples using the QIAamp
DNA formalin fixed paraffin embedded Tissue Kit (Qia-
gen, Valencia, CA) with a modification to the manufac-
turer’s recommended lysis protocol (incubation overnight
at 56C in lysis buffer). DNA concentration and purity
was confirmed via NanoDrop spectrophotometer (Thermo
Scientific, Waltham, MA). We performed sodium bisulfite
modification on 500 ng to 1 lg of DNA using the EZ
DNA Methylation kit (Zymo Research, Orange, CA) in
accord with the manufacturer’s recommended protocol.
Tissue microarray
Formalin-fixed, paraffin-embedded tissue blocks of 110
cases were obtained from the files of the Department of
Pathology, University of Michigan Medical Center, Ann
Arbor, Michigan. The University of Michigan Institutional
Review Board provided a waiver of informed consent to
obtain these samples. After pathological review, a tissue
microarray (TMA) was constructed from the most repre-
sentative area using the methodology of Nocito et al.22
Each case was represented by two 1-mm diameter cores
obtained from the most representative, non-necrotic area
of the tumor.
Immunohistochemistry
Immunohistochemical staining was performed on the
DAKO Autostainer (DAKO, Carpinteria, CA) using dia-
minobenzidine as the chromogen. Serial sections of
deparaffinized TMA sections were labeled with the anti-
bodies listed in Supplementary Table 1, online only.
Appropriate negative (no primary antibody) and positive
controls were stained in parallel with each set of tumors
studied. The immunoreactivity was scored on a 3-tier
scale (negative, low- [11] and high-positive [21]). After
titration of each antibody, and subsequent immunohisto-
chemical (IHC) staining of the 2 TMA slides, the slides
were taken to an experienced pathologist (J.B.M.) for
review and scoring.
Scoring of each stained core on the TMA slides was
carried out using a 2-variable system. The percentage of
malignant cells with positive staining was represented by
a number from 0 to 100. The intensity of staining was
scored on a scale from 0 to 4, in which 0 5 negative, 11
5 0% to 25%, 21 5 26% to 50%, 31 5 51% to 75%,
and 41 5 76% to 100%. As each tumor core was repre-
sented on the TMA in duplicate, the numerical scores of
the 2 cores were averaged separately by percentage and
intensity. The resultant values were then analyzed statisti-
cally using chi-square contrast tests in a linear regression
model to test differences across groups.
Bead array methods
The Illumina Goldengate Methylation Cancer Panel
was utilized to detect DNA methylation patterns in tumor
samples. The Cancer Panel quantifies methylation at 1505
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CpG sites located in known CpG islands across 807 genes
related to cancer, including oncogenes, tumor suppressor
genes, imprinted genes, and genes involved in cell cycle
regulation, DNA repair, apoptosis, and metastasis. Bead
arrays were run at the University of Michigan DNA
Sequencing Core Facility, in accord with the manufac-
turer’s protocol. Briefly, bisulfite converted tumor DNA
was hybridized to the bead array as described previ-
ously,23 and bead arrays were imaged using Illumina Can-
cer Panel Reader software. Raw bead array fluorescence
data was initially analyzed using Illumina BeadStudio
Methylation software, which converts fluorescence values
of the methylated (Cy5) and unmethylated (Cy3) alleles
into an average methylation value at a specific probe
using the formula b 5 [Max(Cy5,0]/[Max(Cy5,0) 1
Max(Cy3,0) 1 100] with b N (0,1).
Methylation at specific CpG probes on the Goldengate
Cancer Panel has been previously shown to be biased by
probe thermodynamic properties.24 Known biases include
probe length and guanine-cytosine content, which can
affect the melting temperature of the probes as well as
probe fluorescence intensities. Thus, we used the method
proposed by Kuan et al24 to normalize our average b val-
ues based on probe length and guanine-cytosine content.
Statistical methods
Unsupervised hierarchical clustering of the methylation
array data was performed using the Euclidean distance
metric and the Ward clustering method in the hclust pack-
age in R version 2.10.1.25 To minimize sex-specific
effects, we excluded CpG sites on the sex chromosomes,
and included the top 50% of CpG sites with the greatest
variance in methylation across samples. For survival anal-
yses, death was considered an “event”; survival time was
censored at 3 years (1095 days). The log-rank test was
used to test differences in survival distributions using the
R Survival package.
Methylation scores
We calculated a tumor suppressor gene methylation score
using our previously described methodology.26 Briefly, we
identified genes associated with tumor suppression by con-
ducting a simple query of the National Center for Biotech-
nology Information gene database for “tumor suppressor”
and extracted gene identifications. A total of 444 individual
CpG sites across 237 genes on the Goldengate Cancer Panel
were linked to tumor suppression. Next, for each study par-
ticipant, the methylation score was defined as the number
of tumor suppressor gene-associated CpG sites with normal-
ized average b values above 0.5. Thus, the methylation
score ranged from 0 to 444. We infer that a higher methyla-
tion score is associated with higher levels of DNA methyla-
tion of promoter regions of genes associated with tumor
suppression and cell cycle regulation.
We also calculated a Polycomb Repressor Complex 2
(PRC2) gene occupancy methylation score for each study
participant. PRC2 target genes were identified in human
embryonic stem cells,27 and are known to be important
regulators of development28 and dysregulated in cancer.29
A total of 232 sites across 107 genes on the Cancer Panel
were identified as PRC2 targets, as described by Lee
et al27. A PRC2 occupancy methylation score was calcu-
lated by summing the number of PRC2-associated CpG
sites with normalized average b values above 0.5. The
PRC2 occupancy methylation scores ranged from 0 to
232. Twenty-six genes were found in both the PRC2
occupancy gene list and the tumor suppressor gene list.
Site specific analyses
To determine whether specific sites of the genome may
be differentially methylated in metastatic cancers, we calcu-
lated associations between DNA methylation and metastatic
potential. The association between metastasis and individual
CpG site DNA methylation at the 1505 CpG sites measured
on the Goldengate Cancer Panel were examined using the
Limma package in R 2.10.1,30 adjusting for sex and age.
Sample weights based on detection p values across samples
were used in the lmFit function from the Limma package to
downweight samples with higher detection p values. An
empirical Bayes method (using the eBayes function in
Limma) was used to shrink standard errors to a common
value and to rank CpG sites in order of differential methyla-
tion. Multiple comparisons were accounted for using the q-
value method previously described.31
RESULTS
Clinical findings of cohort
Our cutaneous SCC study cohort (Table 1) included 46
patients diagnosed with metastatic cutaneous SCC of the
head and neck, including tumors from 41 men and 5
women. The mean age at diagnosis of metastatic disease
was 73 years with a shorter time interval from primary
diagnosis to metastasis of 8.5 months, as compared to
BCC. The most common primary site resulting in
regional metastasis was periauricular (14 of 46; 30%) fol-
lowed by the frontotemporal region (8 of 46; 18%).
Adverse pathological features included perineural inva-
sion (16 of 46; 35%), perivascular invasion (7 of 46;
15%), and bone involvement (3 of 46; 6%). Sixty percent
of patients (28 of 46) were either current or former
smokers. The medial overall survival for patients with
metastatic cutaneous SCC was 4.4 years with no stati-
stical difference at 3 years between metastatic and
TABLE 1. Clinical features of patients with metastatic basal cell








Male : female 4 M : 1 F 41 M : 5 F
Mean age at dx of
metastasis (SD)
65 (8) 73 (11)
Median interval between
primary and met
7 y 8.5 mo
Perineural invasion 5 16
Perivascular invasion 2 7
Bone involvement 5 3




Abbreviations: BCC, basal cell carcinoma; SCC, squamous cell carcinoma; dx, diagnosis; met,
metastasis.
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nonmetastatic patients. There was, however, a trend at 2
years for worse survival in the metastatic cutaneous SCC
cohort (p 5 .08). The demographics of patients with met-
astatic cutaneous SCC are consistent with other reports in
the literature.13–16 The majority of patients were men
(89%) and the most common primary sites involved with
regional metastasis were from the ear (30%) or the fron-
totemporal region (18%). Perineural invasion was present
in 35% of patients, perivascular invasion in 15%, and 18
of 46 patients (39%) of those with metastatic disease
were poorly differentiated on histopathology, compared to
0% of the specimens in the nonmetastatic group.
Our BCC study cohort included 5 patients diagnosed
with verified metastatic basal cell carcinoma (Table 1).
The group consisted of 4 men and 1 woman. The mean
age at the time of primary BCC diagnosis was 55.0,
whereas the mean age at the diagnosis of metastatic dis-
ease was 65 years (range, 52–75 years). Sixty percent of
the patients had multiply recurrent tumors before the
diagnosis of a metastasis. The median interval between
the development of the primary lesion and progression
to clinically evident metastatic disease was 7 years.
Eighty percent of primary sites originated in the facial
region, including the temple, ear, chin, and forehead.
Primary lesions ranged in size from 1.3 cm2 to 70 cm2.
Each of these cases developed metastatic disease in the
neck: 1 patient with level 1 disease, 3 patients with level
2 disease, and the lower back primary had level IV and
V disease along with extensive axillary disease (13 of
17 positive nodes). Histopathologic examination con-
firmed the presence of BCC in all metastatic tumor
specimens, which were identical in subtype to the corre-
sponding primary pathology. All specimens were repre-
sentative of an aggressive growth pattern, and subtypes
included nodular, infiltrative, metatypical, and infiltrat-
ing keratotic, with several cases including mixed fea-
tures. Perineural invasion was present in all cases and
perivascular invasion was evident in 2 of 5 patients.
Only 1 of the 5 patients received radiation before the
development of metastasis because of the extent of the
primary tumor. The other 4 patients received radiation
after resection of the metastases, and only 1 of those
underwent adjuvant chemotherapy. The mean overall
survival time after the development of regional metasta-
ses for the cohort was 4.8 years. Two patients are still
alive, but 1 has distant metastatic disease (lung). For all
the deceased patients, the cause of death is unknown but
each of the 3 was disease free at the date of the last
documented follow-up.
The BCC case cohort of 5 patients is largely represen-
tative of the published literature on age, sex, and ethnic
demographics8–11; we had a male predominance, with the
primary diagnosis in the fifth decade and an extended
interval before clinically apparent metastases were diag-
nosed. All patients had T4 disease based on current
American Joint Committee on Cancer criteria (bone
involvement) and were treated with radical surgical resec-
tion of both the primary disease and regional metastases.
Four of these patients underwent adjuvant radiation, 1 of
whom also received post-chemoradiotherapy (cisplatin).
Despite the comorbidities of these procedures, as well as
the reported median survival of 8 months,11 the shortest
observed survival after surgery was 18 months, and the
median overall survival from the time of definitive surgi-
cal management was almost 5 years.
Methylation patterns
Methylation patterns across all of the 1505 CpG sites
assayed on the Goldengate Cancer Panel were compared
between primary BCC and SCC tissues that did and did
not metastasize. When the top 50% most variable sites
were included in an unsupervised hierarchical clustering
analysis, nonmetastatic BCCs tended to cluster separately
FIGURE 1. Unsupervised hierarchical cluster analysis of DNA methylation identified nonmetastatic basal cell carcinomas (BCCs) (light blue) as hav-
ing a distinct methylation pattern when compared to metastatic BCCs (dark blue), nonmetastatic squamous cell carcinomas (SCCs) (pink), and met-
astatic cutaneous SCCs (red). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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from metastatic BCCs and SCCs (Figure 1). For SCCs,
there was no overall difference in mean methylation
across all sites observed between the 2 groups (Wilcoxon,
p 5 .18), whereas for BCCs the primary tumors that
metastasized were more likely to be hypomethylated
(Wilcoxon, p 5 .07; Figure 2). Additionally, comparing
tumor suppressor methylation score as well as PRC2
occupancy score across metastatic and nonmetastatic pri-
mary BCCs revealed a strong trend that had a similar pat-
tern to that seen with mean methylation, with both tumor
suppressor genes and PRC2 target genes hypomethylated
in metastatic tumors, however, this did not reach statisti-
cal significance (Figure 2). For SCCs, there was no
significant difference in tumor suppressor methylation
score comparing primary tumors that metastasized to
those that did not (Wilcoxon, p 5 .83). Nor was any dif-
ference observed between the 2 groups when comparing
the PRC2 gene occupancy methylation score (Wilcoxon,
p 5 .30).
Site specific methylation analyses of cutaneous
squamous cell carcinomas
To quantify site-specific epigenetic differences between
primary cutaneous SCCs that metastasized and those that
did not, we measured the associations between each of
the 1505 CpG sites on the Goldengate Cancer Panel and
metastatic potential of the tumor. The 10 most differen-
tially methylated sites that were identified are listed in
Table 2. The top hit, a CpG site in the promoter region of
FRZB, a modulator of Wnt signaling known to be
involved in regulation of bone development, was found to
be hypermethylated in metastatic (median methylation:
46.7%) compared to nonmetastatic (median methylation:
4.7%) primary SCCs (p 5 4 3 1025; q 5 0.14). Addi-
tionally, CpG sites associated with the developmental
transcription factors TFAP2C and ASCL2 were also found
to be hypermethylated in metastatic primary SCCs,
whereas CpG sites associated with the actin protein
FIGURE 2. (A) Mean methylation across 1505 CpG sites, (B) tumor suppressor methylation score, and (C) Polycomb Repressor Complex 2 (PRC2) tar-
get methylation score compared between nonmetastatic (n5 7) and metastatic (n5 3) primary basal cell carcinomas (BCCs).
TABLE 2. The 10 most differentially methylated CpG sites associated with metastatic potential of the primary cutaneous squamous cell carcinoma, adjust-
ing for patient age and sex.
Gene Chromosome CpG coordinate Log fold change T value p value Q value
FRZB 2 183439557 2.632 4.612 .0001 0.14
ASCL2 11 2249118 1.635 4.050 .0004 0.29
TFAP2C 20 54638025 1.115 3.840 .0007 0.29
GSTM2 1 110012367 2.501 3.717 .0010 0.29
GSTM1 1 110031602 22.489 23.699 .0010 0.29
TFF1 21 42659893 22.570 23.623 .0012 0.29
RARRES1 3 159933026 21.883 23.587 .0014 0.29
ACTG2 2 73973146 21.565 23.539 .0015 0.29
ACTG2 2 73973699 21.943 23.350 .0025 0.41
NGFB 1 115682393 1.085 3.154 .0040 0.46
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ACTG2 were found to be hypomethylated in metastatic
primary SCCs. We also compared DNA methylation of 4
sites in the FRZB promoter sequence in a subset of the
samples analyzed on the Goldengate Cancer Panel as well
as 10 additional primary SCCs and observed a similar
pattern of methylation based on metastatic potential as
measured on the array (Wilcoxon, p 5 .08; Figure 3).
Site specific methylation analyses of basal cell
carcinomas
To quantify specific epigenetic differences seen in meta-
static and nonmetastatic primary BCCs, we measured the
associations between methylation at each of the 1505 CpG
sites on the Goldengate array to assess the possible
markers of metastatic potential in primary tumors. Two
CpG sites, both associated with the putative tumor
suppressor gene MYCL2 (Figure 4), were found to be sig-
nificantly hypomethylated in metastatic tumors compared
to control primary BCC that did not metastasize (p 5 1.9
3 1026; q 5 0.002 and p 5 3.7 3 1025; q 5 0.028,
respectively). Although not reaching statistical significance
when adjusting for multiple comparisons (q < 0.05), a
number of other genes were also found to be differentially
methylated (p < .05) in metastatic BCCs (Supplementary
Table 2, online only). The majority of these sites were
found to be hypomethylated, similar to the global meas-
ures of methylation presented above, including sites asso-
ciated with EGF, GNG7, GRB10, and FGF9.
Immunohistochemical staining
During preliminary quantification of epigenetic differ-
ences between metastatic and nonmetastatic samples,
numerous candidate genes were identified as potentially
associated with metastatic potential. To investigate
whether this differential methylation was reflected in pro-
tein expression, IHC staining was performed on a subset
of the proteins for which IHC antibodies are commer-
cially available (Supplementary Table 1, online only).
After the construction of a TMA that included patho-
logical specimens from both cutaneous SCC and BCC
FIGURE 3. In cutaneous squa-
mous cell carcinoma (SCC),
methylation of the FRZB pro-
moter was quantified by (A) the
Goldengate methylation panel
or (B) pyrosequencing of 4 CpG
sites in the FRZB promoter.
FIGURE 4. Two CpG sites asso-
ciated with MYCL2 were found
to be significantly hypomethy-
lated in basal cell carcinomas
(BCCs) that became metastatic
(p 5 1.9 3 1026; q 5 0.002
and p 5 3.7 3 1025; q 5
0.028, respectively).
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groups, tissue from metastatic and nonmetastatic tumors
were used for IHC staining. Staining scores were then
compared between the groups; however, a significant dif-
ference in protein expression that differentiated metastatic
from nonmetastatic primary tumors was discovered in
only 1 case. When comparing the intensity of staining
across cutaneous SCC samples, a neurotrophin receptor
kinase, TrkB (also known as NTRK2), was identified by
this process as being more highly expressed in SCC pri-
maries that went on to metastasize compared to those that
did not. Notably, this data reflects the highly elevated
staining intensity of only 3 specimens of 26 stained in the
metastatic SCC group, all of which scored 2 on a 0 to 4
scale. This, when compared to the 6 cores of 70 with pos-
itive staining in the nonmetastatic group, all of which
received an intensity score of 1, achieved statistical sig-
nificance in our model. IHC staining of BCC samples did
not yield any significant differences between metastatic
and nonmetastatic tissues.
DISCUSSION
In addition to reviewing our clinical experience with
metastatic cutaneous SCC and BCC, we undertook a
study of the epigenetic signatures in primary tumors that
developed regional or distant metastatic disease to deter-
mine how to identify patients who might be at high risk
of developing metastatic cutaneous SCC or BCC. We
identified epigenetic predictors of metastatic potential in
both cutaneous SCC and BCC, with metastatic cutaneous
SCC primaries hypermethylated at FRZB and metastatic
BCC primaries hypomethylated at MYCL2. Additionally,
we identified that metastatic primary cutaneous SCCs
were more likely to stain positive for TrkB, with a higher
staining intensity, although this relationship was driven
by a small number of cases.
Despite a small sample size, our comprehensive experi-
mental analysis of epigenetic regulation in metastatic
cutaneous SCC and BCC was adequately powered to
detect significant differences in methylation signatures
between groups. When comparing epigenetic profiles
between metastatic versus nonmetastatic primary cutane-
ous SCCs, we did not see widespread differences in meth-
ylation patterns, but did identify differential methylation
at a CpG site in the promoter region of FRZB. The pro-
tein product of FRZB is secreted and involved in regula-
tion of bone morphogenesis during development32,33
through antagonism of Wnt signaling.34,35 Previous stud-
ies of the role of FRZB in cancer have identified that
overexpression of FRZB is associated with a more differ-
entiated tumor phenotype in gastric cancer,25 as well as a
less invasive phenotype in prostate cancer.36 Additionally,
promoter methylation of FRZB was associated with a
higher grade in noninvasive bladder cancer cases.37 Simi-
larly, in this study, we observed increased promoter meth-
ylation in primary cutaneous SCC tumors that
metastasized. Our results, combined with previous find-
ings, suggest that FRZB methylation could serve as a
biomarker of tumor aggressiveness or metastatic potential
at multiple cancer sites.
We observed widespread methylation differences
between metastatic and nonmetastatic primary BCCs.
Metastatic BCCs were found to be hypomethylated across
the genome, as well as at tumor suppressor genes and
PRC2 target genes (Figure 2). Additionally, we found that
in an unsupervised hierarchical cluster analysis, nonmeta-
static primary BCCs clustered separately from the rest of
the tumors, suggesting a unique methylation profile (Fig-
ure 1). In gene specific analyses, MYCL2 was the only
gene to show a significantly different methylation score
across metastatic and nonmetastatic primaries, and this
was observed at both loci included on the array. This
gene localizes to the X-chromosome, has a poorly charac-
terized function, and has previously been described as
highly and specifically expressed in testes.38 MYCL2
shares sequence homology with the tumor suppressor
genes MYCL1 and MYC. In these samples, MYCL2 was
unmethylated in metastatic BCCA and methylated in non-
metastatic BCCA, suggesting that methylation at these
loci could be used as biomarkers of metastatic potential.
Of interest in the gene list with borderline significance,
GNG7, involved in transmembrane signaling, has been
shown to be hypermethylated in head and neck SCC39
and fibroblast growth factor 9 (FGF9) is upregulated in
cutaneous SCCs.40
IHC staining for a range of proteins, including EGFR
and RUNX3, did not reveal significant differences in
expression when comparing primary tumors that metasta-
sized and those that did not. Interestingly, despite the dif-
ferences observed in methylation of FRZB in metastatic
cutaneous SCCs, we did not observe a significant differ-
ence in protein expression between metastatic and nonme-
tastatic primaries. We did, however, observe a significant
increase in staining intensity of TrkB in metastatic cuta-
neous SCCs. TrkB has been described previously as an
important oncogene in head and neck cancer, medullary
thyroid carcinoma, myelomas, prostate cancer, and
lymphoid tumors.41–44 The small number of metastatic
cases that stained positively for TrkB suggests that there
may be a subset of cutaneous SCCs in which metastasis
is driven, in part, by TrkB overexpression.
There exists an ongoing debate as to whether BCC
truly metastasizes, with some arguing that it is rather the
cells of a primary lesion with squamous cell differentia-
tion that initiate invasion and spread of disease, acting as
a vehicle for BCC cells to disseminate. However, the
pathology of our BCC specimens, both primary and meta-
static, consistently demonstrates the features of BCC on
histologic analysis. Interestingly, however, the primary
BCCs that developed metastases had a methylation pat-
tern that strongly clustered with cutaneous SCC (see Fig-
ure 1). This cluster profile was shared with both primary
cutaneous SCC that metastasized and those that did not
metastasize, which would suggest that metastatic BCCs,
at least when viewed from a gene methylation perspec-
tive, more closely resembles cutaneous SCC. Perhaps
analysis of the gene methylation profiles of high-risk
BCC might offer clues to those primaries at greatest risk
of regional and distant metastases and could offer the
possibility of increased surveillance or the use of adjuvant
treatments, such as the hedgehog pathway inhibitor (vis-
modegib) for high-risk lesions.
This study has elucidated definitive differences in epi-
genetic signatures among the metastatic forms of cutane-
ous SCC and BCC. FRZB and MYCL2 may be putative
DARR ET AL.
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biomarkers of the metastatic phenotype and useful in
future diagnosis and prevention of advanced disease.
However, our data highlight the need for additional
research on this subject; mechanistic and mutational data
remains elusive because of the relative rare nature of this
process. However, epigenetic modification of functionally
important genes may hold special significance in the
improved management of metastatic cutaneous disease.
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